BIOMAT Database Logo BIOMAT Database Logo

Structure-activity studies on 2-aryl-4H-3,1-benzoxazin-4-ones. 1994

J A Hadfield, and V H Pavlidis, and A T McGown, and C Whitworth, and P J Perry, and B W Fox
CRC Department of Experimental Chemotherapy, Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK.

Eight benzoxazin-4-ones related in structure to NSC 341964 (1) have been tested for cytotoxicity in two different cell systems. Two of the benzoxazin-4-ones (3 and 10) showed good cytotoxicity (ID50 = 9.9 and 8.9 microM) in P388 cells. The nitrobenzoxazin-4-one (10) caused a significant alteration in cell cycle distribution when administered to P388 cells and was an inhibitor of porcine pancreatic elastase. Structure-activity relationships are discussed.

UI MeSH Term Description Entries
D007624 KB Cells This line KB is now known to be a subline of the ubiquitous KERATIN-forming tumor cell line HeLa. It was originally thought to be derived from an epidermal carcinoma of the mouth, but was subsequently found, based on isoenzyme analysis, HeLa marker chromosomes, and DNA fingerprinting, to have been established via contamination by HELA CELLS. The cells are positive for keratin by immunoperoxidase staining. KB cells have been reported to contain human papillomavirus18 (HPV-18) sequences. HeLa-KB Cells,Cell, HeLa-KB,Cell, KB,Cells, HeLa-KB,Cells, KB,HeLa KB Cells,HeLa-KB Cell,KB Cell
D007941 Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene. P388D(1) Leukemia,P388, Leukemia
D008811 Mice, Inbred DBA An inbred strain of mouse. Specific substrains are used in a variety of areas of BIOMEDICAL RESEARCH such as DBA/1J, which is used as a model for RHEUMATOID ARTHRITIS. Mice, DBA,Mouse, DBA,Mouse, Inbred DBA,DBA Mice,DBA Mice, Inbred,DBA Mouse,DBA Mouse, Inbred,Inbred DBA Mice,Inbred DBA Mouse
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D010196 Pancreatic Elastase A protease of broad specificity, obtained from dried pancreas. Molecular weight is approximately 25,000. The enzyme breaks down elastin, the specific protein of elastic fibers, and digests other proteins such as fibrin, hemoglobin, and albumin. EC 3.4.21.36. Elastase,Pancreatopeptidase,Elastase I,Pancreatic Elastase I,Elastase I, Pancreatic,Elastase, Pancreatic
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D005260 Female Females

Related Publications

J A Hadfield, and V H Pavlidis, and A T McGown, and C Whitworth, and P J Perry, and B W Fox
Studies on 2-benzyloxy-4H-3,1-benzoxazin-4-ones as serine protease inhibitors.
July 1998, Pharmaceutica acta Helvetiae,
J A Hadfield, and V H Pavlidis, and A T McGown, and C Whitworth, and P J Perry, and B W Fox
2-Phenyl-4H-3,1-benzoxazin-4-one.
December 2008, Acta crystallographica. Section E, Structure reports online,
J A Hadfield, and V H Pavlidis, and A T McGown, and C Whitworth, and P J Perry, and B W Fox
Inhibition of cathepsin G by 4H-3,1-benzoxazin-4-ones.
October 1997, Bioorganic & medicinal chemistry,
J A Hadfield, and V H Pavlidis, and A T McGown, and C Whitworth, and P J Perry, and B W Fox
2-amino-4H-3,1-benzoxazin-4-ones as inhibitors of C1r serine protease.
March 1998, Journal of medicinal chemistry,
J A Hadfield, and V H Pavlidis, and A T McGown, and C Whitworth, and P J Perry, and B W Fox
Inhibition of chymotrypsin and pancreatic elastase by 4H-3,1-benzoxazin-4-ones.
January 1991, Journal of enzyme inhibition,
J A Hadfield, and V H Pavlidis, and A T McGown, and C Whitworth, and P J Perry, and B W Fox
Hypolipidemic 2-[4-(1,1-dimethylethyl)phenyl]-4H-3,1-benzoxazin-4-ones. Structure-activity relationships of a novel series of high-density lipoprotein elevators.
January 1989, Journal of medicinal chemistry,
J A Hadfield, and V H Pavlidis, and A T McGown, and C Whitworth, and P J Perry, and B W Fox
Facile synthesis and herbicidal evaluation of 4H-3,1-benzoxazin-4-ones and 3H-quinazolin-4-ones with 2-phenoxymethyl substituents.
March 2012, Molecules (Basel, Switzerland),
J A Hadfield, and V H Pavlidis, and A T McGown, and C Whitworth, and P J Perry, and B W Fox
Benzenesulfonamide derivatives of 2-substituted 4H-3,1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease.
March 1999, Bioorganic & medicinal chemistry letters,
J A Hadfield, and V H Pavlidis, and A T McGown, and C Whitworth, and P J Perry, and B W Fox
1H and 13C NMR spectral studies of some 4H-3,1-benzoxazin-4-ones and their 2-acylaminobenzoic acid precursors.
May 2000, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy,
J A Hadfield, and V H Pavlidis, and A T McGown, and C Whitworth, and P J Perry, and B W Fox
Synthesis of amidrazones from 2-ethoxycarbonyl-4H-3,1-benzoxazin-4-one.
January 1982, Die Pharmazie,
Copied contents to your clipboard!